factually
Index/Topics/APOE-e4 carrier status and ARIA risk

APOE-e4 carrier status and ARIA risk

The relationship between APOE-e4 carrier status and the risk of amyloid-related imaging abnormalities (ARIA) with lecanemab and donanemab treatments.

Fact-Checks

1 result
Jan 15, 2026
Most Viewed

How does APOE‑ε4 carrier status change the management and MRI surveillance schedule for patients on lecanemab or donanemab?

APOE‑ε4 carrier status meaningfully raises the risk of amyloid‑related imaging abnormalities (ARIA) with both lecanemab and donanemab, and that elevated risk has been translated into mandatory APOE ge...